FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
-
A bibliometric study of the top 100 most-cited articles on melanoma: insights into research trends and characteristics
598PDF: 341SUPPLEMENTARY MATERIAL: 183HTML: 20 -
28 | Efficacy and toxicity outcomes with doublet immunotherapy in metastatic melanoma: the real-world REALIPINIVO study Miriam Forte1, Francesco Caraglia1, Silvana Cozzolino1, Antonino Colloca1, Alfonso Esposito1, Maria Cristina Giugliano1, Eleonora Cioli1, Marcella Scala2, Francesca Sparano5, Maria Chiara Sergi3, Teresa Del Giudice4, Immacolata Paciolla6, Luigi Formisano2, Stefania Napolitano1, Antonio Maria Grimaldi6, Paolo Antonio Ascierto5, Fortunato Ciardiello1, Teresa Troiani1, Vincenzo De Falco1 | 1Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples; 2Department of Clinical Medicine and Surgery, Federico Il University, Naples; 3Unità Operativa Complessa di Oncologia Medica, Ospedale "Mons. A.R. Dimiccoli", Barletta; 4Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; 5Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Napoli; 6Medical Oncology Unit AORN "San Pio", Benevento, Italy.
447 -
24 | IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL E. Filippi1, M. Lebwohl2, A. Blauvelt3, C. Kartman4, C. Leatherwood4, K. Gordon5, N. Sattar6, L. Puig7, J. Merola8, K. Siu4, R. Wang4, L. Sun4, A. Leung9, N. Somani4, M. Rueda4, A. Cardoso4, M. Genovese4, A. Armstrong10, B. Strober11 | 1Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy; 2Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3Blauvelt Consulting, LLC, Annapolis, MD, USA; 4Eli Lilly and Company, Indianapolis, IN, USA; 5Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; 6School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; 7Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain; 8Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; 9Syneos Health, Morrisville, NC, USA; 10Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA; 11Department of Dermatology, Yale University School of Medicine, New Haven, CT, Central Connecticut Dermatology Research, Cromwell, CT, USA
119PDF: 42 -
Blue diode laser as supportive therapy for the management of vulvar lichen sclerosus
2695PDF: 833SUPPLEMENTARY MATERIAL: 280HTML: 153 -
31 | Effectiveness and safety of adjuvant combo-targeted and immunotherapy in melanoma patients Valentina Salizzato1, Luisa Piccin1, Alessio Fabozzi2, Paolo Del Fiore3, Francesco Cavallin4, Chiara Cacco1|5, Simone Mocellin3|5, Marcodomenico Mazza3, Valentina Guarneri1|5, Jacopo Pigozzo1 | 1Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova; 2Medical Oncology 3, Veneto Institute of Oncology IOV-IRCCS, Padova; 3Soft-Tissue, Peritoneum and Melanoma Surgical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova; 4Independent Statistician, Solagna; 5Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy.
364
